Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

Interlocutory appeals in MDLs

By Bexis on December 7, 2006
Email this postTweet this postLike this postShare this post on LinkedIn

We love choice of law issues for federal questions in MDLs; it gives us something to think about.
Readers of this blog know the basic issue. A lawsuit is filed in federal court in, say, New York. The New York court enters an order (on a federal question) that is appropriate under Second Circuit law. The MDL Panel then transfers the case to, say, Chicago, and Seventh Circuit law on the relevant point differs from Second Circuit law. Should the Chicago court reconsider the order entered in New York?
Whether or not it does, the Chicago court then rules on other substantive issues that arise under federal law (such as, say, preemption). The Chicago court applies Seventh Circuit precedent. (On that issue, at least, the law has been relatively uniform for the last two decades. Since In re Korean Air Lines Disaster, 829 F.2d 1171 (D.C. Cir. 1987), MDL transferee courts have generally applied local federal precedent on matters of federal law.)
After pretrial proceedings are concluded, the MDL Panel transfers the case away from Chicago and back to New York for trial. Second Circuit law on the substantive issue differs from Seventh Circuit law. Should the New York court reconsider the order entered in Chicago?
These issues are generally resolved under the “law of the case” doctrine, which is a tad amorphous to begin with. And we hate even to type these next words, but consider this: Federal precedent on the law of the case doctrine varies by circuit. Should courts apply Second Circuit or Seventh Circuit precedent on “law of the case” when deciding the issues discussed above? One scholar grappled with this question years ago: Joan Steinman, “Law of the Case: A Judicial Puzzle in Consolidated and Transferred Cases and in Multidistrict Litigation,” 135 U. Pa. L. Rev. 595 (1987).
But here’s what grabbed our eye. In the Enron MDL, Judge Harmon recently refused to certify an interlocutory appeal in part on the ground that certifying an appeal in an MDL wouldn’t do much good, since the constituent cases would ultimately be remanded for trial in different circuits:

“because this is a multidistrict litigation, many of the consolidated member suits arose in other Circuit Courts of Appeals. . . . Thus the Fifth Circuit’s determination of the questions may not be controlling.”

In re Enron Corporation Securities, Derivative & ERISA Litigation, MDL No. 1446, slip op. at 5 (S.D. Tex. Nov. 21, 2006).
Isn’ there a decent argument grounded in law of the case that cuts in favor of certifying an appeal in this situation? The law of the case doctrine instructs courts to defer to some extent to decisions made by coordinate courts. Thus, trial courts defer to decisions made by other trial courts. But appellate courts also defer to decisions made in a single case by other appellate courts. See Wright, Miller & Cooper, Federal Practice and Procedure: Jurisdiction 2d Sec. 4478.4 at 780 (2002). Thus, if Judge Harmon had certified the appeal to the Fifth Circuit, other circuit courts might well have deferred to that decision under the law of the case doctrine, making it more likely that all of the Enron cases would ultimately be controlled by a single set of rules.
In future MDLs, defendants should consider asking MDL transferee courts to certify appeals for the express purpose of obtaining appellate precedents that may apply unusually broadly because of the deference they might deserve under the law of the case doctrine.

Photo of Bexis Bexis

JAMES M. BECK is Reed Smith’s only Senior Life Sciences Policy Analyst, resident in the firm’s Philadelphia office. He is the author of, among other things, Drug and Medical Device Product Liability Handbook (2004) (with Anthony Vale). He wrote the seminal law review…

JAMES M. BECK is Reed Smith’s only Senior Life Sciences Policy Analyst, resident in the firm’s Philadelphia office. He is the author of, among other things, Drug and Medical Device Product Liability Handbook (2004) (with Anthony Vale). He wrote the seminal law review article on off-label use cited by the Supreme Court in Buckman v. Plaintiffs Legal Committee. He has written more amicus briefs for the Product Liability Advisory Council than anyone else in the history of the organization, and in 2011 won PLAC’s highest honor, the John P. Raleigh award. He has been a member of the American Law Institute (ALI) since 2005. He is the long-time editor of the newsletter of the ABA’s Mass Torts Committee.  He is vice chair of the Class Actions and Multi-Plaintiff Litigation SLG of DRI’s Drug and Device Committee.  He can be reached at jmbeck@reedsmith.com.  His LinkedIn page is here.

Read more about BexisEmailJames's Linkedin Profile
Show more Show less
  • Posted in:
    Class Action & Mass Torts
  • Blog:
    Drug & Device Law
  • Organization:
    Drug & Device Law Blogging Team
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo